Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
Launched by EXPERIMENTAL AND CLINICAL RESEARCH CENTER, A COOPERATION BETWEEN THE MAX DELBRÜCK CENTER FOR MOLECUL · Oct 31, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Acute Optic Neuritis Network, is looking at people who are experiencing their first episode of acute optic neuritis, which is inflammation of the optic nerve that can affect vision. The study aims to understand how quickly treatment with corticosteroids (a type of medication) can help with visual recovery after this condition and to explore differences between various types of optic neuritis linked to conditions like multiple sclerosis. Researchers will gather information through various tests, including eye examinations, MRI scans, and questionnaires about participants' quality of life and any pain or depression they might be experiencing.
To be eligible for this study, participants must be at least 18 years old and have had their first acute optic neuritis episode with visual symptoms starting within the last 30 days. They also need to be able to provide written consent to join. Those with prior conditions related to the optic nerve or other serious health issues may not be able to participate. If you join the study, you can expect to undergo a series of assessments to help researchers learn more about this condition and improve future treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • First-ever acute ON
- • Onset of visual symptoms within maximum of 30 days
- • Age ≥ 18 years
- • Ability to give written informed consent
- • Presence of written consent
- Exclusion Criteria:
- • MRI contraindication
- • Prior demyelinating diagnosis
- • Diagnosis of other forms of optic neuropathy (hereditary, granulomatous, infectious, infiltrative, toxic)
- • Pregnancy at inclusion
- • Relevant other diseases that conflict with study participation according to protocol
- • Inability to cooperate
About Experimental And Clinical Research Center, A Cooperation Between The Max Delbrück Center For Molecul
The Experimental and Clinical Research Center (ECRC) is a collaborative initiative between the Max Delbrück Center for Molecular Medicine and esteemed clinical institutions, dedicated to advancing biomedical research and innovation. The ECRC focuses on bridging the gap between laboratory discoveries and clinical applications, fostering a multidisciplinary environment that promotes the development of novel therapeutic strategies. By integrating cutting-edge molecular techniques with rigorous clinical methodologies, the ECRC aims to enhance patient care and improve treatment outcomes through high-quality clinical trials and translational research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Jerusalem, , Israel
Bologna, , Italy
Buenos Aires, , Argentina
Verona, , Italy
Aurora, Colorado, United States
Barcelona, , Spain
Gaborone, , Botswana
Bogotá, , Colombia
Rochester, Minnesota, United States
Sydney, , Australia
Minas Gerais, , Brazil
Bogotá, , Colombia
Bogotá, , Colombia
Odense, , Denmark
Lyon, , France
Berlin, , Germany
Munich, , Germany
Mangalore, , India
Tel Aviv, , Israel
Fukushima, , Japan
Seúl, , Korea, Republic Of
Barcelona, , Spain
Birmingham, , United Kingdom
Oxford, , United Kingdom
Lusaka, , Zambia
Patients applied
Trial Officials
Susanna Asseyer
Principal Investigator
Charite University, Berlin, Germany
Hadas Stiebel-Kalish
Principal Investigator
Rabin Medical Center, Tel Aviv
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials